Peptide Decoding
← All guides
News

Does the AMA Vote End BPC-157 Compounding? What Its New Policy Can Do

By Allison Thorne · Editorial standards
Published November 11, 2026
Six small vials of pale blue liquid in a row on a printed document, on a dark desk with a white coat over the chair behind

On November 9, 2026, the American Medical Association voted to urge HHS and the FDA to "immediately rescind" any policy that makes it easier to compound peptides the FDA has not approved.1 The vote does not end BPC-157 compounding. HHS's interim policy of October 30, covering BPC-157, TB-500 and four other peptides, is still in place.23

The AMA is a doctors' association, not a regulator. Only HHS can withdraw its own policy, and the AMA did not name it.4 Its timing points there anyway. Public comments on the HHS policy close on November 13, 2026, four days after the vote.2

What did the AMA adopt?

The AMA adopted a policy with three parts, set out in its November 9 release from the Interim Meeting of its House of Delegates in Orlando.1 Its House of Delegates is the AMA's policy-making body, made up of delegates from state and specialty medical societies.

HHS interim policy AMA policy
Issued by HHS Office of the Secretary2 American Medical Association House of Delegates1
Date Published October 30, 20262 Announced November 9, 20261
What it does Says federal regulators will not take enforcement action against pharmacies compounding six listed peptides under set conditions3 Urges regulators to rescind such policies, and commits the AMA to push for enforcement and to educate1
Peptides named BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-5003 None by name; "synthetic peptides" without FDA approval14
Legal force Interim and not binding on HHS or the public2 None over regulators; it directs the AMA's own advocacy
Next step Comments close November 13, 20262 Lobbying federal agencies and state boards1

First comes the call on HHS, the FDA and other federal regulators to rescind.1 A second part commits the AMA to work with federal agencies, state medical boards and state boards of pharmacy on strict oversight and "swift enforcement" against compounding pharmacies, direct-to-consumer telehealth platforms and online dispensaries distributing unapproved peptide formulations.1 Last is education for physicians and the public on safety risks and missing efficacy data.4

AMA board member Ilse Levin said the substances "have not undergone the rigorous testing required of FDA-approved drugs" and that patients "are at increased risk of serious harm."1

The policy does not name the HHS policy or any peptide, as Becker's noted.4 Its target is plain from the timing and from the AMA's own November 6 statement on the HHS policy, covered below.

There is one small conflict on the date. The AMA's release is dated November 9 and its site describes the meeting as concluding that day.1 Inside Health Policy reported the House of Delegates passing the resolution on Tuesday, November 10.5 The AMA's own release is the stronger source, and the one-day gap changes nothing in substance.

Does this end BPC-157 compounding?

No. Nothing in the AMA's vote has legal effect on pharmacies, and the HHS policy has not been withdrawn or revised.12 A pharmacy compounding one of the six peptides under the policy's conditions is in the same position on November 11 as it was on November 8.

HHS left itself room to change course. It describes the policy as interim, running while the formal list of substances pharmacies may compound is built through rulemaking, and it states that the policy "is not binding on HHS or the public."2 HHS has also said it may revisit the policy in whole or in part if a safety signal or quality problem appears.3 HHS can end it without a court ruling or new rulemaking, and the AMA's vote is a request that it do so.

What does the HHS policy actually allow?

The HHS policy lets state-licensed pharmacies and licensed physicians compound six peptides for individual patients with a prescription, without FDA enforcement, if they meet a list of conditions.3 The six are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.3

On paper, the conditions are strict. Each compounded product may contain only one listed peptide, so a BPC-157 and TB-500 blend does not qualify.3 The raw peptide has to come from an FDA-registered manufacturer, and the policy's appendix lists fifteen categories of testing, including sterility, endotoxin and identity.3 Our full reading of the policy is in what HHS allowed.

Is the AMA right that the evidence is missing?

On efficacy in people, largely yes, and FDA's own reviewers said much the same before the policy existed. At the FDA advisory committee meeting of July 23 to 24, 2026, the agency's career reviewers recommended against all seven peptides under review.6 The committee overruled them on six, voting 8 to 6 with one abstention for BPC-157, and rejected only DSIP.6 Our account of that meeting is in the July 2026 peptide vote.

For BPC-157 the record is thin in a specific way. No completed human efficacy trial has been published for any use, and the four registered trials have posted no results, the furthest a Phase 2 still under way.7 The full record is on the BPC-157 page.

Missing trials are not proof of harm, and the AMA's release cites no injury from compounded peptides.1 Its quality worry is the part the HHS policy tries hardest to answer, with single-ingredient products, a registered manufacturer and fifteen categories of testing.3 Testing can confirm what is in a vial, but not whether the peptide does anything for the person using it.

Who else has objected to the policy?

This is the AMA's second objection in a week. Its November 6 advocacy update said the HHS policy puts patients at risk and listed what is missing for these peptides: characterized formulations, validated pharmacokinetics, toxicology and safety data, dosing parameters including routes, and quality specifications.8 It also flagged inconsistent naming of the compounds.8 Pharmacokinetics means how the body absorbs, distributes and clears a drug.

FDA's own scientists objected before the policy appeared. The Associated Press reported on October 28, from six people familiar with the process, that FDA scientific staff had little input and opposed the changes.9 The AP described the document as written mainly by HHS officials. It called HHS leading compounding policy extremely rare.9 An HHS spokesperson told the AP the policy offers "a more controlled alternative through licensed U.S. compounders."9

The November 9 policy turns that advocacy statement into a position adopted by the AMA's full House of Delegates.

Where could the AMA actually have an effect?

The AMA's likeliest point of influence is the states. Doctors are licensed by state medical boards and pharmacies by state boards of pharmacy, and those boards can discipline their own licensees whatever a federal enforcement policy says. Its new policy names those boards as partners for enforcement.1

Boards have acted on peptides before without any federal change. In June 2026 the Alabama Board of Medical Examiners warned physicians that research-grade peptides are prohibited for administering or dispensing to patients.10 A search on November 11, 2026 found no board action responding to the AMA vote, and the AMA's release names none.1 In Washington, the path is narrower. HHS chose this policy over objections from FDA staff, so a request from a medical society may not move it.9

What changes for someone with a vial?

Nothing changes directly for a vial bought online. The HHS policy only ever covered compounding by licensed pharmacies and physicians for a named patient with a prescription.3 A vial bought from an online research-peptide seller was outside it before the AMA vote and is outside it now. That outside market is the larger one: our November 11, 2026 price capture lists BPC-157 at 216 vendors.7

Online sellers come up in one place in the AMA policy: its enforcement push against "online dispensaries" and direct-to-consumer telehealth platforms.1 Telehealth clinics that prescribe peptides through compounding pharmacies are the channel most exposed if state boards respond. Gray-market sellers already operate outside the compounding system, so a board action against pharmacies would not reach them.

For a buyer, the checks are the same as last week: a per-lot certificate of analysis with the lot printed on the vial, a seller on our vendor list with no open FDA letter, and a test of the first vial. How to vet a vendor and how to read a COA cover each step.

What is not known?

  • Whether HHS will respond. No response to the AMA had been reported as of November 11.4
  • How many comments the docket will receive, and whether HHS will revise the policy after it closes.
  • Whether any state medical or pharmacy board will act on the AMA's call.
  • The exact resolution text and vote count. The AMA's release summarizes the policy; we have not seen the adopted resolution itself.1

What happens next?

Public comments on the HHS policy close November 13, 2026, under docket HHS-OASH-2026-0496.2 After that, HHS can leave the interim policy as it is, revise it or withdraw it. Separately, FDA's rulemaking on the permanent compounding list continues, and five more peptides are due before FDA's advisers, covered in our February 2027 panel preview.

Common questions

Did the AMA ban BPC-157?

No. The AMA cannot ban anything. It adopted a policy asking federal regulators to rescind rules that ease peptide compounding.

Is the HHS peptide policy still in effect?

Yes. As of November 11, 2026, HHS has not withdrawn or revised it.

Can a compounding pharmacy still make BPC-157?

Under the HHS policy, yes, for a named patient with a prescription and under the policy's conditions. The AMA vote did not change that.

What exactly did the AMA vote for?

It urges HHS and FDA to immediately rescind policies easing compounding of unapproved synthetic peptides. It also commits the AMA to push enforcement with state boards and to educate doctors and the public.

Which peptides does the AMA policy name?

None. It refers to synthetic peptides without FDA approval. The HHS policy it targets covers BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.

When did the AMA adopt it?

The AMA announced it on November 9, 2026, at its Interim Meeting in Orlando. One trade outlet reported the vote as November 10.

Is the AMA a government agency?

No. It is a private professional association of physicians. Its House of Delegates sets the AMA's own positions and advocacy.

Can HHS cancel the peptide policy?

Yes. The notice calls the policy interim and not binding, and HHS has said it may revisit it if safety or quality problems appear.

When does the comment period end?

November 13, 2026. The notice opened two weeks of comments from its October 30 publication.

Where do I comment on the HHS peptide policy?

On the federal docket HHS-OASH-2026-0496 at regulations.gov, until November 13, 2026.

Does this affect peptides I buy online?

Not directly. The HHS policy never covered research-peptide sellers, and the AMA vote has no legal force over them.

Could state boards act on this?

They could. State medical and pharmacy boards license doctors and pharmacies, and the AMA says it will work with them. None had acted as of November 11.

Does it affect telehealth peptide clinics?

Possibly, later. The AMA named direct-to-consumer telehealth platforms in its enforcement push, but nothing has been done against any clinic as a result.

Did FDA scientists support the HHS policy?

No, according to the Associated Press. Six people familiar with the process said FDA scientific staff had little input and opposed it.

What did the AMA say was missing?

Formulation data, pharmacokinetics, toxicology and safety data, dosing and routes, and quality specifications. It listed those in its November 6 advocacy update.

Is there clinical trial evidence for BPC-157?

Not from a completed trial. No human efficacy trial has been published for any use, and the registered trials have posted no results.

Is BPC-157 FDA approved?

No. The HHS policy is an enforcement decision, not an approval of any peptide.

Sources

  1. American Medical Association. "AMA adopts new policies to protect patients and strengthen public health." Press release, November 9, 2026. https://www.ama-assn.org/press-center/ama-press-releases/ama-adopts-new-policies-protect-patients-and-strengthen-public
    Read at source (through a fetch tool that caps quotation near 125 characters). Section "Protecting the public against unapproved synthetic peptides and enforcing patient safety." A summary of the adopted policy, not the resolution text; names no peptide and no specific HHS policy; gives no vote count. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
  2. U.S. Department of Health and Human Services, Office of the Secretary. "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Notice of availability, Federal Register document 2026-22192, docket HHS-OASH-2026-0496, October 30, 2026. https://govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
    Read at source. Comments run two weeks from publication (November 13, 2026, by calculation; the notice gives no calendar date). States the policy is interim and not binding. The appendix listing the peptides is a separate HHS document. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
  3. Peptide Decoding. "Can You Get BPC-157 From a Compounding Pharmacy Now? What HHS Allowed." October 29, 2026. https://peptidedecoding.com/news/bpc-157-compounding-hhs-policy
    Read at source, site's own reading of the HHS policy and its Appendices A and B. The HHS appendix PDFs were not re-read for this page. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
  4. "New AMA policy targets unapproved peptide compounding." Becker's Hospital Review, November 10, 2026. https://www.beckershospitalreview.com/glp-1s/new-ama-policy-targets-unapproved-peptide-compounding/
    Read at source. Confirms the policy names no peptide or specific policy; reports no HHS response. ↩ ↩ ↩ ↩ ↩
  5. Jessica Karins. "AMA Calls On HHS To Rescind Peptide Access Policy." Inside Health Policy, November 11, 2026. https://insidehealthpolicy.com/daily-news/ama-calls-hhs-rescind-peptide-access-policy
    Subscription article; only the headline and first sentence were read. Source of the November 10 vote date, which conflicts with the AMA's November 9 release. ↩
  6. Peptide Decoding. "The July 2026 Peptide Vote: The Record, and What It Is Worth." July 28, 2026. https://peptidedecoding.com/guides/july-2026-peptide-vote
    Read at source, site's own account of the FDA Pharmacy Compounding Advisory Committee meeting of July 23 to 24, 2026. ↩ ↩
  7. Peptide Decoding. BPC-157 compound page (human-trial record; price summary of 216 vendors and 623 listings, last read November 11, 2026). https://peptidedecoding.com/peptides/bpc-157
    Read at source, site's own data. The page summarizes four registered trials without NCT numbers. ↩ ↩
  8. American Medical Association. "Nov. 6, 2026: National Advocacy Update," section "HHS non-enforcement peptide policy puts patients at risk." https://www.ama-assn.org/health-care-advocacy/advocacy-update/nov-6-2026-national-advocacy-update
    Read at source. An advocacy statement, not adopted House policy. ↩ ↩
  9. Matthew Perrone. "FDA scientists opposed the Trump administration's effort to ease peptides access." Associated Press, October 28, 2026, as republished by ClickOrlando. https://www.clickorlando.com/business/2026/10/28/fda-scientists-opposed-the-trump-administrations-effort-to-ease-peptides-access/
    Read via a reproduction (syndicated copy). Rests on six unnamed sources; no internal document is quoted. ↩ ↩ ↩ ↩
  10. "Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides." Drug Topics, June 5, 2026. https://www.drugtopics.com/view/alabama-board-of-medical-examiners-issues-warning-of-non-fda-approved-peptides
    Read at source. A trade report of the board's notice; the board's own release was not opened. ↩

Citing this page: Peptide Decoding. Does the AMA Vote End BPC-157 Compounding? What Its New Policy Can Do. Figures and dates from the AMA release of November 9, 2026 and the HHS notice of October 30, 2026. Reviewed November 11, 2026. https://peptidedecoding.com/news/ama-hhs-peptide-policy